Indeed, compared to the CD4+ T cells from RA patients where Th17 overrided the Treg response (Figure 4J), treatment with 5-AzaC resulted in the shift from Th17 to Treg responses (Figures 8C, D, H–J) and increased Treg cytokine IL-10 while suppressing IL-6 and INF-γ release by the CD4+ T cells from RA patients (Figure 7D, E, H). Here, CD4 is linked to rheumatoid arthritis.